A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Brian GM Durie, MD
AMyC
Principal Investigator - Jatin Shah, MD
AMyC
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
- Indiana University Simon Cancer Center
Indianapolis, Indiana, United States
- the John Theurer Cancer Center @ Hackensack Umc
Hackensack, New Jersey, United States
- Columbia University
New York, New York, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
- University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2011
- Primary completion
- 31 Jul 2020
- Completion
- 31 Jul 2020
- Last update posted
- 1 Aug 2022
- Registered enrollment
- 136
- Registry id
- NCT01464034
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.